A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)

被引：0

作者：

Morris, Michael J.

Wong, Jeffrey Y. C.

Nordquist, Luke

Szmulewitz, Russell Zelig

Agarwal, Neeraj

Attiyeh, Edward F.

Max, Steven I.

Divgi, Chaitanya R.

Patricia, Daniel

Cao, Yu

Li, Xiang

Yu, Alex

Urtishak, Karen

Lauring, Josh David

Sartor, Oliver

机构：

[1] Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, New York, NY 10021 USA

[2] City Hope Natl Med Ctr, Dept Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA

[3] XCanc Omaha, Omaha, NE USA

[4] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA

[5] Huntsman Canc Inst, Salt Lake City, UT USA

[6] Janssen Res & Dev LLC, Spring House, PA USA

[7] Mayo Clin, Rochester, MN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5010

引用

页数：1

共 50 条

[31] PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN PATIENTS (PTS) WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) FOLLOWING ABIRATERONE AND/OR ENZALUTAMIDE (ABI/ENZ): RESULTS FROM A PHASE 2 STUDY
Petrylak, Daniel
Vogelzang, Nicholas
Chatta, Kamal
Fleming, Mark
Smith, David
Appleman, Leonard
Hussain, Arif
Modiano, Manuel
Singh, Parminder
Tagawa, Scott
Gore, Ira
McClay, Ed
Mega, Anthony
Sartor, Oliver
Somer, Brad
Wadlow, Raymond
Shore, Neal
Stambler, Nancy
DiPippo, Vincent
Israel, Robert
JOURNAL OF UROLOGY, 2015, 193 (04): : E1040 - E1040
[32] Final analysis of the phase 1b/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent.
Markowski, Mark Christopher
Eisenberger, Mario A.
Pieczonka, Christopher Michael
Getzenberg, Robert H.
Rodriguez, Domingo
Barnette, K. Gary
Steiner, Mitchell S.
Saltzstein, Daniel R.
Antonarakis, Emmanuel S.
Tutrone, Ronald F.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[33] A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.
Kelly, William Kevin
Hussain, Arif
Saraiya, Biren
Thanigaimani, Pradeep
Sun, Furong
Seebach, Frank A.
Lowy, Israel
Sandigursky, Sabina
Miller, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[34] Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
Jimmy L. Zhao
Emmanuel S. Antonarakis
Heather H. Cheng
Daniel J. George
Rahul Aggarwal
Elyn Riedel
Takayuki Sumiyoshi
Joseph D. Schonhoft
Amanda Anderson
Ninghui Mao
Samuel Haywood
Brooke Decker
Tracy Curley
Wassim Abida
Felix Y. Feng
Karen Knudsen
Brett Carver
Mario E. Lacouture
Alexander W. Wyatt
Dana Rathkopf
British Journal of Cancer, 2024, 130 : 53 - 62
[35] Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
Zhao, Jimmy L.
Antonarakis, Emmanuel S.
Cheng, Heather H.
George, Daniel J.
Aggarwal, Rahul
Riedel, Elyn
Sumiyoshi, Takayuki
Schonhoft, Joseph D.
Anderson, Amanda
Mao, Ninghui
Haywood, Samuel
Decker, Brooke
Curley, Tracy
Abida, Wassim
Feng, Felix Y.
Knudsen, Karen
Carver, Brett
Lacouture, Mario E.
Wyatt, Alexander W.
Rathkopf, Dana
BRITISH JOURNAL OF CANCER, 2024, 130 (01) : 53 - 62
[36] PHASE 1B/2 STUDY OF BXCL701, AN ORAL ACTIVATOR OF THE SYSTEMIC INNATE IMMUNITY PATHWAY, COMBINED WITH PEMBROLIZUMAB (PEMBRO), IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Aggarwal, Rahul
Costin, Dan
Zhang, Jingsong
Monk, Paul
Linch, Mark
Karsh, Lawrence
Healey, Diane
Corsi-Travali, Stefani
Adurthi, Sreenivas
Adedoyin, Adedayo
O'Neill, Vincent
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A208 - A209
[37] PHASE 2 RESULTS FROM A PHASE 1/2 STUDY OF TAK-700 (ORTERONEL), AN ORAL, INVESTIGATIONAL, NONSTEROIDAL 17,20-LYASE INHIBITOR, WITH DOCETAXEL AND PREDNISONE (DP) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Petrylak, D. P.
Gandhi, J. G.
Clark, W. R.
Heath, E. I.
Lin, J.
Oh, W. K.
Agus, D. B.
Carthon, B.
Moran, S.
Liu, G.
ANNALS OF ONCOLOGY, 2012, 23 : 302 - 303
[38] Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.
Sweeney, Christopher
Percent, Ivor John
Babu, Sunil
Cultrera, Jennifer
Mehlhaff, Bryan Allyn
Goodman, Oscar B.
Morris, David
Schnadig, Ian D.
Albany, Costantine
Shore, Neal D.
Sieber, Paul R.
Guba, Susan
Wang, Minmin
Kang, Suhyun
Wacheck, Volker
Donoho, Gregory P.
Szpurka, Anna M.
Callies, Sophie
Lin, Boris K.
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[39] Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer
Tagawa, Scott T.
Vallabhajosula, Shenker
Christos, Paul J.
Jhanwar, Yuliya S.
Batra, Jaspreet S.
Lam, Linda
Osborne, Joseph
Beltran, Himisha
Molina, Ana M.
Goldsmith, Stanley J.
Bander, Neil H.
Nanus, David M.
CANCER, 2019, 125 (15) : 2561 - 2569
[40] DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A subgroup analysis of a phase 1/2 multicenter study.
Patel, Manish R.
Johnson, Melissa Lynne
Falchook, Gerald Steven
Doi, Toshihiko
Friedman, Claire Frances
Piha-Paul, Sarina Anne
Gutierrez, Martin
Shimizu, Toshio
Cheng, Ben
Qian, Meng
Qian, Xiaozhong
Myobatake, Yusuke
Laadem, Abderrahmane
Yoshizuka, Naoto
Hammett, Tracey
Kirui, Julius
Arkenau, Hendrik-Tobias
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)

← 1 2 3 4 5 →